Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. DeMichele · SciRah

Researcher profile · Semantic Scholar

A. DeMichele

Share profile

A. DeMichele — researcher profile on SciRah

h-index: 89
Works: 627
Citations: 28K

Most-cited papers

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer
E. Mayer, Yue Ren, N. Wagle, R. Mahtani +25 more
2024Journal of Clinical Oncology83 citations
Semantic Scholar
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomised I-SPY2.2 phase 2 trial
R. Shatsky, M. Trivedi, C. Yau, Rita Nanda +56 more
2024Nature Medicine55 citations Open access
Semantic Scholar
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.
V. Geurts, S. Balduzzi, T. Steenbruggen, S. Linn +15 more
2024JAMA Oncology52 citations Open access
Semantic Scholar
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
A. DeMichele, A. Clark, E. Shea, L. Bayne +25 more
2025Nature Medicine47 citations
Semantic Scholar
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
O. Metzger, S. Mandrekar, Shom Goel, J. Gligorov +35 more
2026New England Journal of Medicine31 citations
Semantic Scholar
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.
C. Denkert, S. Rachakonda, T. Karn, K. Weber +36 more
2025Cancer Cell26 citations Open access
Semantic Scholar
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer
S. Tolaney, A. DeMichele, T. Takano, H. Rugo +10 more
2024Future Oncology26 citations Open access
Semantic Scholar
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
G. Villacampa, T. Pascual, P. Tarantino, J. Cortés +32 more
2025The Lancet Oncology22 citations
Semantic Scholar
Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors
M. Magbanua, N. Manon, D. Wolf, S. Rivero-Hinojosa +21 more
2025Nature Communications20 citations Open access
Semantic Scholar
Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
N. Tung, Feng-Min Zhao, A. DeMichele, A. Prat +16 more
2025Journal of Clinical Oncology19 citations Open access
Semantic Scholar
Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial.
Steve M. Kawut, Rui Feng, S. Ellenberg, R. Zamanian +16 more
2024American Journal of Respiratory and Critical Care Medicine19 citations Open access
Semantic Scholar
Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.
I. Makhlin, L. Fallowfield, N. Henry, H. J. Burstein +2 more
2024JCO Oncology Practice12 citations
Semantic Scholar
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
N. Hunter, H. A. Parsons, Leslie Cope, J. Canzoniero +32 more
2026Journal of Clinical Oncology10 citations
Semantic Scholar
Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial).
N. Hunter, Heather A. Parsons, Leslie Cope, J. Canzoniero +16 more
2025Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial
R. Mukhtar, K. Dimitroff, C. Yau, J. Chien +32 more
2025Annals of Surgical Oncology10 citations
Semantic Scholar
Rare subclonal sequencing of breast cancers indicates putative metastatic driver mutations are predominately acquired after dissemination
Matthew R. Lawrence-Paul, Tien-Chi Pan, D. Pant, N. Shih +5 more
2024Genome Medicine10 citations Open access
Semantic Scholar
ECOG-ACRIN EAZ171: Prospective validation trial of germline predictors of taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer
Bryan P. Schneider, Feng-Min Zhao, T. Ballinger, Sofia F. Garcia +20 more
2024Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
Michael J. Campbell, D. Wolf, C. Yau, L. Brown-Swigart +22 more
2024Cell Reports Medicine10 citations Open access
Semantic Scholar
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy
M. Magbanua, Ziad Ahmed, R. Sayaman, Lamorna Brown Swigart +14 more
2024Clinical Cancer Research9 citations Open access
Semantic Scholar
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
H. Wildiers, Virginie Adam, Seamus O'Reilly, J. Van Cauwenberge +49 more
2025JAMA Oncology8 citations Open access
Semantic Scholar
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
H. Rugo, Mike Campbell, C. Yau, J. Chien +19 more
2024Breast Cancer Research and Treatment8 citations Open access
Semantic Scholar
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
G. Nader-Marta, C. Singer, D. Hlauschek, A. DeMichele +17 more
2024Breast Cancer Research8 citations Open access
Semantic Scholar
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer
Wen Li, N. Onishi, J. Gibbs, L. Wilmes +13 more
2025Tomography7 citations Open access
Semantic Scholar
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
R. Mukhtar, Soumy Gottipati, C. Yau, S. López-Tarruella +42 more
2025npj Breast Cancer6 citations Open access
Semantic Scholar
Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6
E. Taranto, A. DeMichele
2026npj Breast Cancer5 citations Open access
Semantic Scholar
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
D. Wolf, C. Yau, M. Campbell, A. Glas +31 more
2025JCO Precision Oncology5 citations Open access
Semantic Scholar
485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC)
I. Vaz-Luis, G. Mazza, J. Gligorov, E. Lim +16 more
2025Annals of Oncology4 citations Open access
Semantic Scholar
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study.
L. Gerratana, C. Reduzzi, Yue Ren, R. Jeselsohn +19 more
2025Clinical Cancer Research4 citations
Semantic Scholar
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer
J. Balko, Xiao-Peng Sun, Ann Hanna, Andres A. Ocampo +15 more
2025Research Square4 citations
Semantic Scholar
Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial
J. Tseng, K. Dimitroff, C. Sauder, A. Chien +39 more
2026Annals of Surgical Oncology3 citations Open access
Semantic Scholar
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer
Xiao-Peng Sun, Andres A. Ocampo, Ann Hanna, Brandie C. Taylor +15 more
2026Science Translational Medicine3 citations Open access
Semantic Scholar
Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.
C. Denkert, S. Rachakonda, A. Pehl, F. Marmé +33 more
2026Modern Pathology3 citations Open access
Semantic Scholar
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial
J. van Hassel, K. Dimitroff, C. Yau, R. Mukhtar +29 more
2025Annals of Surgical Oncology3 citations Open access
Semantic Scholar
Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
R. Mukhtar, K. Dimitroff, C. Yau, L. J. van 't Veer +16 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Abstract PS9-03: Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study
E. Taranto, N. Seewald, L. Bayne, E. Walinsky +23 more
2025Clinical Cancer Research3 citations
Semantic Scholar
HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer.
P. Shah, Alexandra Torres, Megan Aaron, Vivek Narayan +6 more
2024Journal of Clinical Oncology3 citations
Semantic Scholar
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate–Ribose) Polymerase-1–Targeted 18F-Fluorthanatrace PET in Breast Cancer
A. Young, A. Pantel, Mahsa Kiani, R. Doot +16 more
2024Journal of Nuclear Medicine3 citations Open access
Semantic Scholar
Adjuvant Platinum versus Capecitabine for Residual Invasive Triple-Negative Breast Cancer: Patient-Reported Outcomes in ECOG-ACRIN EA1131
Karen L. Smith, Feng-Min Zhao, I. Mayer, Amye J. Tevaarwerk +21 more
2024Cancer3 citations
Semantic Scholar
Pathologic complete response (pCR) rate and factors associated with pCR after taxane, trastuzumab, and pertuzumab in HER2-positive breast cancer: secondary analyses of EA1181
N. Tung, Feng-Min Zhao, A. DeMichele, A. Prat +28 more
2026Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Abstract P2-07-25: Thymidine kinase activity as a prognostic and predictive biomarker in the Phase II PACE trial of CDK4/6 inhibition beyond progression
Nader-Marta, Yue Ren, R. Mahtani, Cynthia X. Ma +19 more
2025Clinical Cancer Research2 citations
Semantic Scholar
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021
A. Thomas, A. Rhoads, E. Mayer, Seamus O'Reilly +10 more
2025npj Breast Cancer2 citations Open access
Semantic Scholar
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).
M. Hennessy, C. Gatsonis, H. Jacene, R. Connolly +13 more
2025Future Oncology2 citations Open access
Semantic Scholar
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis
E. Hahnen, J. Hauke, K. Gelmon, F. Marmé +34 more
2025JCO Precision Oncology2 citations Open access
Semantic Scholar
Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
A. Thomas, D. Wolf, R. Balassanian, Yunni-Yi Chen +16 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.
J. Meisel, Katia Khoury, A. Chien, A. Wallace +15 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias
D. Hlauschek, N. Dandachi, M. Gnant, Heather A. Parsons +4 more
2026EBioMedicine1 citations Open access
Semantic Scholar
Abstract RF4-01: Central Nervous System Outcomes from the Phase III PATINA Trial (AFT-38)
O. Metzger, S. Mandrekar, T. Dockter, L. Gianni +12 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial
Moriah Forster, Feng-Min Zhao, Sarah Bell, I. Mayer +25 more
2026JCO oncology advances1 citations Open access
Semantic Scholar
Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.
Amrita Basu, S. Umashankar, D. Wolf, C. Yau +15 more
2025Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Abstract PS11-01: [18F]Fluoroestradiol (FES)-PET as a predictive measure for endocrine therapy in patients with newly diagnosed metastatic breast cancer: Results from EAI142
Hannah M. Linden, Fenghai Duan, Farrokh Dehdashti, A. Fowler +16 more
2025Clinical Cancer Research1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Yau×15
Invite
C. Yau — researcher profile on SciRah
H. Rugo×13
Invite
H. Rugo — researcher profile on SciRah
L. J. van 't Veer×13
Invite
L. J. van 't Veer — researcher profile on SciRah
W. Symmans×10
Invite
W. Symmans — researcher profile on SciRah

×9

Invite

R. Shatsky — researcher profile on SciRah

Invite

G. Hirst — researcher profile on SciRah

J. Perlmutter×9

Invite

J. Perlmutter — researcher profile on SciRah

Invite

D. Yee — researcher profile on SciRah

Invite

L. Esserman — researcher profile on SciRah

Invite

L. Esserman — researcher profile on SciRah

Invite

D. Wolf — researcher profile on SciRah

Invite

R. Nanda — researcher profile on SciRah